Neither form replaces the other. The more useful question is not which one wins, it is where each form ends up in the body and what it is actually known to do there.
A Vitamin K1 (Phylloquinone) test measures circulating phylloquinone in serum or plasma, usually by liquid chromatography on a standard venous draw, often collected fasting because a recent fatty meal can lift the value. Phylloquinone clears quickly, so one result reflects recent intake more than long term stores. Labs commonly report it against a typical reference range of about 0.1 to 5 ng/mL, and FitScript's optimal range is 0.2 to 3.2 ng/mL, an optimization target rather than a diagnostic cut-off. Reference ranges vary by lab, age and sex. The biomarker page linked above covers collection, interpretation and what a high or low phylloquinone result may reflect in detail, so the rest of this guide stays on the comparison itself.
Both forms share an identical business end and differ only in the tail attached to it. Every vitamin K molecule carries the same 2-methyl-1,4-naphthoquinone ring, and that ring is what allows the vitamin to act as a cofactor for the enzyme gamma-glutamyl carboxylase. The side chain is where they split. Phylloquinone (K1) carries a single saturated phytyl tail. The menaquinones (K2) carry a chain of unsaturated isoprene units, and they are named for how many of those units they have, so MK-4, MK-7, MK-9 and so on.
That tail is not cosmetic. It changes how the molecule is packaged into lipoproteins, how long it survives in circulation, and which tissues get a share of it. Research suggests that this structural difference, rather than any difference in the ring chemistry, explains why K1 and K2 behave so differently in the body despite doing the same biochemical job at the molecular level 1.
The job itself is simple to describe. Vitamin K lets the carboxylase enzyme convert specific glutamate residues on certain proteins into gamma-carboxyglutamate, or Gla. Only once that conversion happens can those proteins bind calcium and work. So K1 and K2 are not two vitamins with two mechanisms. They are two delivery vehicles for one mechanism, arriving in different places.
| Feature | Vitamin K1 (phylloquinone) | Vitamin K2 (menaquinones, MK-n) |
|---|---|---|
| Side chain | Single saturated phytyl tail | Unsaturated isoprenoid chain, varying length |
| Main dietary sources | Green leafy vegetables, some plant oils | Fermented foods, cheese and curd, egg yolk, liver and some meats |
| Share of intake in most diets | The larger share | The smaller share |
| Where it mostly goes | Taken up strongly by the liver | Longer chain forms distribute more widely to tissues outside the liver |
| Time in circulation | Short, cleared within hours | Longer for long chain forms such as MK-7 |
| Best established role | Carboxylation of clotting factors | Carboxylation of Gla proteins outside the liver, such as osteocalcin and matrix Gla protein |
| Main area of interest | Deficiency, bleeding, coagulation status | Bone quality, vascular calcification |
| Routinely measured in blood? | Yes, as serum phylloquinone | Rarely, not on routine panels |
K1 comes from plants and K2 comes mostly from fermentation and animal tissue. Phylloquinone sits inside chloroplasts, so the greener and leafier the vegetable, the more it tends to carry. Kale, collards, spinach, Swiss chard, broccoli, Brussels sprouts, cabbage, lettuce and herbs such as parsley are the usual contributors, along with certain plant oils including soybean, canola and olive oil. Because phylloquinone is bound in plant membranes, it is absorbed less efficiently from raw greens than from greens eaten with some fat.
Menaquinones arrive by other routes. Bacterial fermentation produces them, which is why fermented soybean preparations are unusually rich in MK-7, and why hard and soft cheeses, curd and other fermented dairy contribute longer chain forms. Egg yolk, liver, chicken and some other meats carry MK-4. Part of the MK-4 found in animal tissue is not strictly dietary at all, since tissues can convert phylloquinone into MK-4 locally. Gut bacteria also synthesise long chain menaquinones in the colon, although how much of that is actually absorbed and used remains uncertain 2.
The practical consequence is that total vitamin K intake and menaquinone intake are two different things. Someone eating a large salad daily can have a generous phylloquinone intake and still take in very little K2, because almost nothing in that salad is fermented. Conversely, a diet heavy in cheese, eggs and organ meat can supply menaquinones while supplying modest phylloquinone. Food frequency, not a single food, is what shapes the pattern.
The two forms part company almost immediately after absorption. Vitamin K is fat soluble, so both forms are absorbed in the small intestine alongside dietary fat, packaged into chylomicrons and sent into the lymphatic system. From there, the liver pulls phylloquinone out of circulation efficiently and uses it to carboxylate clotting factors. Phylloquinone leaves the blood quickly and body stores of it are small, which is why circulating levels swing with what was eaten recently 2.
Long chain menaquinones behave differently. After the initial chylomicron phase, they are redistributed onto other lipoproteins and remain in circulation substantially longer, which gives tissues outside the liver more opportunity to take them up. Studies indicate that this longer residence time and broader tissue distribution are the main pharmacokinetic reasons menaquinones have been investigated for roles beyond coagulation 1.
There is a hierarchy in how the body spends what it has. When vitamin K is scarce, hepatic carboxylation of clotting factors is prioritised, and the Gla proteins outside the liver are served last. That is one reason a person can have entirely normal coagulation tests while proteins such as osteocalcin and matrix Gla protein remain partly uncarboxylated. Normal clotting does not confirm that every vitamin K dependent process in the body is fully supported.
K1 is the dominant form for coagulation in most people. The clotting factors II, VII, IX and X, along with the anticoagulant proteins C, S and Z, are all vitamin K dependent Gla proteins made in the liver, and the liver's strong uptake of phylloquinone makes it the main substrate for that work. When vitamin K is insufficient, those factors are released in an undercarboxylated, poorly functional state.
Classic signs of insufficiency reflect that. Easy bruising, prolonged bleeding from small cuts, nosebleeds, heavy menstrual bleeding or a prothrombin time that lengthens without another explanation are the patterns clinicians look for. Prothrombin time and INR are the familiar tests, but they are relatively insensitive and only move once the shortfall is substantial. Research suggests that undercarboxylated prothrombin, often reported as PIVKA-II, detects inadequate vitamin K status earlier than conventional coagulation testing does 3.
Newborns are the one group where vitamin K status is universally addressed rather than investigated, because placental transfer is limited, breast milk is low in vitamin K and the infant gut is not yet colonised. Routine newborn prophylaxis exists for that reason and is handled entirely by the clinical team.
Menaquinones can support coagulation too, since the ring chemistry is identical, but in ordinary diets K1 supplies the bulk of what the liver uses. If the question is simply which form keeps the clotting cascade running, the answer is K1, with K2 as a contributor rather than the main source.
The bone case rests on osteocalcin, a Gla protein made by bone-forming cells that requires vitamin K to become fully carboxylated. In its carboxylated form, osteocalcin binds calcium and associates with the bone matrix. Undercarboxylated osteocalcin, measured as ucOC, is used as a functional readout of vitamin K status in bone tissue, and it tends to fall when vitamin K intake rises.
From there, things get more interesting and less settled. Reviews describe a plausible mechanistic role for vitamin K in bone quality and calcium handling, working alongside vitamin D rather than independently of it 4. Randomised trials have mostly looked at menaquinone forms in postmenopausal populations, and a systematic review and meta-analysis of those trials reported findings that research suggests favour menaquinone supplementation for bone mineral density outcomes in postmenopausal osteoporosis, while flagging heterogeneity between trials and variation in study quality 5.
Those caveats matter. The menaquinone forms, durations and populations vary widely, and bone mineral density is a surrogate endpoint rather than a fracture count. The honest summary is that vitamin K is clearly part of bone biochemistry, that menaquinones are the forms most studied for it, and that the clinical size of the effect is still being worked out. Nothing here replaces the standard assessment of bone health, which a clinician directs.
The vascular interest centres on matrix Gla protein, or MGP, which is produced in the artery wall and acts as a local inhibitor of calcification once it is carboxylated. Without enough vitamin K, MGP circulates in a dephosphorylated, uncarboxylated form known as dp-ucMGP, which is used as a marker of vascular vitamin K status and tends to be higher when intake is low.
Observational work has repeatedly looked at menaquinone intake and cardiovascular outcomes, and a narrative review of that literature reports that higher vitamin K2 intake is associated with less arterial calcification and more favourable cardiovascular findings in population studies, while noting that intervention trials have been smaller and less consistent 6. Association is not causation, and dietary patterns rich in fermented foods differ in many other ways too.
What can be said fairly is this. The mechanism is real and well characterised, MGP carboxylation genuinely depends on vitamin K, and dp-ucMGP responds to vitamin K status. Whether moving that marker changes hard cardiovascular outcomes over a lifetime is a different question, and the trial evidence has not settled it. Calcification is also driven by factors such as kidney function, blood pressure, lipoprotein burden, glucose control and age, so vitamin K is one input among many rather than the lever that overrides the rest. Anyone with a known calcification finding should have it interpreted by their clinician in that wider context.
They come up together because they act on the same calcium pathway from different angles. Vitamin D influences how much calcium is absorbed and raises the expression of vitamin K dependent proteins such as osteocalcin, while vitamin K is required to activate those proteins once they exist. The reasoning is that producing more of a protein helps less if a cofactor needed to switch it on is in short supply.
This combination has been tested directly. A meta-analysis of randomised controlled trials examining vitamin K and vitamin D together reported results that evidence suggests favour the combination over either nutrient alone for some measures of bone quality, although the included trials varied in design and population 7. A broader review of calcium, vitamin D, vitamin K2 and magnesium in skeletal health reaches a similar position, describing the nutrients as interdependent contributors to bone rather than interchangeable single fixes 8.
The practical reading is to think in terms of the whole calcium handling system rather than one nutrient at a time. Vitamin D status is measurable and routinely tested, magnesium and calcium are measurable, and parathyroid hormone gives context on how hard the body is working to defend its calcium level. Vitamin K sits inside that same system. Interpreting any of them in isolation, including a single phylloquinone value, tends to produce a narrower answer than the biology deserves.
The two forms sit at very different levels of evidential certainty. The role of vitamin K in coagulation is foundational physiology, demonstrated through deficiency states, through the mechanism of vitamin K antagonist drugs and through the response of coagulation markers to vitamin K status 3. Nobody seriously disputes it, and K1 is the main dietary contributor to that function.
The extrahepatic story is newer and softer. The mechanisms behind osteocalcin and matrix Gla protein are well described, and markers such as ucOC and dp-ucMGP move in the directions the mechanisms predict. The weak link is the step from marker change to clinical outcome. Which menaquinone form was used, for how long, in whom and with what endpoint all vary, and surrogate endpoints are common.
So a fair comparison reads as follows. K1 is well established for clotting and is the form most diets supply. K2 is biologically plausible for bone and vascular endpoints, but whether it changes clinical outcomes there is not established. That is a reason to take vitamin K intake seriously as part of a broader dietary pattern, not a reason to expect any single supplement to settle a bone or cardiovascular question. Supplement choices, including whether any supplement is appropriate at all, belong in a conversation with a clinician who knows the rest of the picture, particularly medication history.
Not in the way a vitamin D test shows vitamin D status. Serum phylloquinone is widely available and reflects recent K1 intake, but routine panels do not report menaquinone concentrations, and assays for individual MK forms are not routinely available. There is no single widely available number that sums up K2 status.
What exists instead are functional markers, which measure the consequence of vitamin K availability rather than the vitamin itself. Undercarboxylated osteocalcin reflects vitamin K sufficiency at the level of bone, and dephosphorylated uncarboxylated matrix Gla protein reflects it at the level of the vessel wall. PIVKA-II reflects hepatic status. Reviews of vitamin K assessment describe these functional markers as more informative about tissue level status than a single circulating vitamin concentration, while noting that standardisation and availability remain limiting 3.
There is also a timing problem worth understanding. Because phylloquinone clears within hours and intake varies day to day, one serum value can look low after a few days of minimal greens and unremarkable after a salad-heavy weekend, in a person whose longer term pattern has not changed 2. A result that sits outside the typical range is worth repeating and worth interpreting alongside diet history, fat absorption and medications rather than being read as a verdict on its own.
Shortfalls cluster in situations where fat absorption, bile flow or dietary variety is compromised. Because both forms need fat and bile to be absorbed, in people with cystic fibrosis, celiac disease, inflammatory bowel disease, exocrine pancreatic insufficiency or cholestatic liver disease, vitamin K status can drift low even when intake looks adequate on paper. The same applies after certain bariatric procedures that reduce absorptive surface or alter fat digestion.
Other contributors are less obvious. Very low intake of green vegetables over a long period narrows the main K1 supply. In people with advanced chronic kidney disease, markers such as dp-ucMGP are frequently elevated. Severe liver disease complicates matters further, since the liver both stores and uses the vitamin and also manufactures the clotting factors that depend on it.
For most healthy adults eating a varied diet, frank vitamin K deficiency with bleeding is uncommon. The more common scenario in an optimization context is subtler, a pattern of modest intake combined with markers suggesting incomplete carboxylation elsewhere in the body. That is an observation worth discussing, not a diagnosis. Overt vitamin K toxicity from food forms has not been described in the way it has for some other fat soluble vitamins, although that is not an argument for indiscriminate supplementation 2.
This is the single most important safety point on the page. Some medications that affect blood clotting work by blocking the enzyme that recycles vitamin K, which deliberately reduces carboxylation of clotting factors. Their effect is therefore sensitive to how much vitamin K arrives from food and supplements. A sudden increase in vitamin K intake can blunt the medication's effect, and a sudden decrease can amplify it. Both directions change bleeding and clotting risk, which is why INR is monitored.
The guidance that follows from this is consistency, not avoidance. People on these medications are generally advised to keep their vitamin K intake steady rather than to eliminate greens, and any change in diet pattern or any new supplement containing vitamin K, in either the K1 or K2 form, should be raised with the prescriber first. Do not start, stop or change a vitamin K containing supplement while on a vitamin K antagonist without that conversation. A licensed provider evaluates whether any such change is appropriate and how monitoring should be adjusted.
It is worth knowing that some newer blood thinners do not act through the vitamin K cycle, so they are not subject to the same dietary interaction. That does not mean supplements are automatically fine on them, since other interactions and bleeding considerations still apply, and the prescriber remains the right person to ask. Anyone unsure which category their medication falls into should check with their pharmacist or prescriber rather than guess.
Vitamin K is best read next to the rest of the calcium and bone system, not alone. The most directly relevant companions are 25-hydroxyvitamin D, calcium, albumin (because it affects how calcium is reported), magnesium, phosphate, parathyroid hormone and alkaline phosphatase. Together these describe how calcium is being absorbed, defended and deposited, which is the system vitamin K acts within.
A second group speaks to absorption. A lipid panel, liver enzymes, bilirubin and markers of inflammation give context on fat digestion and bile flow, and low levels of other fat soluble vitamins alongside a low phylloquinone result point toward an absorption question rather than a dietary one. Prothrombin time or INR adds the coagulation view where there is bleeding or bruising to explain.
Testing several of these at once is usually more informative than chasing one value, because the pattern across markers is what suggests where the limitation sits. FitScript's membership is built around that idea, with 150+ biomarkers tested per year and interpretation from Atlas, FitScript's AI health advisor, which reads the markers against each other rather than one line at a time. Whatever the panel, the interpretation step is what converts numbers into something useful, and a clinician should be involved when a result is abnormal or when medications are in play.
Sooner rather than later in a few specific situations. Unexplained easy bruising, bleeding gums, frequent nosebleeds, blood in stool or urine, or unusually heavy menstrual bleeding are worth discussing with a clinician promptly, because coagulation status is something that should be assessed rather than self-interpreted. The same urgency applies to any bleeding symptom in someone taking medication that affects blood clotting.
A non-urgent conversation makes sense in other cases. In people with a known fat malabsorption condition, cholestatic liver disease, advanced kidney disease or a history of bariatric surgery, vitamin K status is reasonable to review as part of broader nutrient monitoring. Anyone considering a vitamin K containing supplement while taking any medication that affects blood clotting should speak to their prescriber before starting. Anyone with osteoporosis, osteopenia or a vascular calcification finding should have vitamin K discussed as one piece of a management approach that a clinician directs, not as a substitute for it.
This article is educational information and not medical advice. Discuss your own results, symptoms and any treatment or supplement decision with a clinician or licensed provider who can see your full history, your medications and the rest of your laboratory picture. A single phylloquinone value, high or low, does not establish a diagnosis on its own, and no result should be ignored because an article described it as common.
For related reading on fat soluble vitamin status and how it shows up day to day, see does low vitamin d cause fatigue and does vitamin d affect sleep.
Neither is simply better, because they do the same biochemical job in different places. K1 supplies most of what the liver uses for clotting factors, while longer chain K2 forms stay in circulation longer and reach tissues outside the liver. A varied diet usually supplies both, and whether any supplement is appropriate is a question for a clinician who knows your medications and history.
Partly. Tissues can convert phylloquinone into MK-4, which is one reason MK-4 appears in animal tissues, and gut bacteria in the colon produce longer chain menaquinones. How much of that bacterial production is absorbed and used is still uncertain, so conversion and gut synthesis are not treated as a reliable substitute for dietary intake of menaquinones.
Not necessarily. Serum phylloquinone clears within hours and tracks recent intake, so one value reflects the last day or two more than longer term status. The body also prioritises clotting factor carboxylation when vitamin K is scarce, which means coagulation tests can look normal while proteins such as osteocalcin and matrix Gla protein remain partly uncarboxylated. Interpretation is best done alongside diet history, absorption markers and related nutrients.
Fermented foods and certain animal foods. Fermented soybean preparations are notably rich in MK-7, and hard and soft cheeses and other fermented dairy contribute longer chain menaquinones. Egg yolk, liver, chicken and some other meats contribute MK-4. Green vegetables, by contrast, supply K1 rather than K2, so a salad-heavy diet can be high in total vitamin K and still low in menaquinones.
People taking a blood thinner that works against vitamin K are generally advised to keep vitamin K intake consistent rather than to avoid it, because sudden increases or decreases change how the medication behaves and shift bleeding and clotting risk. No vitamin K containing supplement should be started, stopped or changed without speaking to the prescriber first. Newer blood thinners do not act through the vitamin K cycle, but a prescriber or pharmacist should still be consulted.
Because they act on the same calcium pathway from different angles. Vitamin D influences calcium absorption and raises the expression of vitamin K dependent proteins, and vitamin K is required to activate those proteins once they are made.
Not as a routine panel item. Serum phylloquinone is widely available, but individual menaquinone assays are not routinely offered. Vitamin K status in bone and vessel wall is instead assessed indirectly through functional markers such as undercarboxylated osteocalcin and dephosphorylated uncarboxylated matrix Gla protein, both of which have limited standardisation.
The calcium system companions are the most useful, so 25-hydroxyvitamin D, calcium, albumin, magnesium, phosphate, parathyroid hormone and alkaline phosphatase. A lipid panel, liver enzymes and bilirubin add context on fat absorption and bile flow, and prothrombin time or INR is relevant where there is bruising or bleeding to explain. The pattern across several markers is usually more informative than any single value, and a clinician should interpret abnormal results.